Company intelligence / Profile preview

SeneXta Therapeutics SA

Lugano, Switzerland

Ownership: Private
Development stage: Phase 1

Overview

The company has conducted early clinical studies for their lead compound Methanesulfonyl fluoride (MSF), which demonstrated good safety in Alzheimer's patients and encouraging signs of activity in preclinical models of dementia[5][7].

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Partnerships

University of Texas at El Paso (UTEP)Transparency Life Sciences

Beyond the preview

Go deeper on SeneXta Therapeutics SA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SeneXta Therapeutics SA.

Explore the full profile